Blood coagulation and its regulation by anticoagulant pathways: Genetic pathogenesis of bleeding and thrombotic diseases

Journal of Internal Medicine

Volumn 257, Issue 3, 2005, Pages 209-223

  Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

APC resistance; Factor V Leiden; Haemophilia; Protein C; Protein S; Von Willebrand's disease

Indexed keywords

ACTIVATED PROTEIN C; ADENOSINE DIPHOSPHATE; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; CD36 ANTIGEN; FIBRINOPEPTIDE; FIBRONECTIN; GLYCOPROTEIN IB; HEPARIN; INTEGRIN; LOW MOLECULAR WEIGHT HEPARIN; METALLOPROTEINASE; METALLOPROTEINASE ADAMTS 13; PROTEIN C; PROTEIN S; PROTHROMBIN A; SEROTONIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; THROMBOSPONDIN; THROMBOXANE A2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BERNARD SOULIER DISEASE; BLEEDING DISORDER; BLOOD CLOTTING; DEFENSE MECHANISM; DISSEMINATED INTRAVASCULAR CLOTTING; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS; VON WILLEBRAND DISEASE;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; BLOOD PROTEINS; HEMOPHILIA A; HEMORRHAGE; HUMANS; MODELS, BIOLOGICAL; PROTEIN C; THROMBOSIS;

EID: 14844292593     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01444.x     Document Type: Review

References (122)

1. George JN. Platelets. Lancet 2000; 355: 1531-9.
2. Majerus PW. Platelets. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, eds. The Molecular Basis of Blood Disease, 3rd edn. Philadelphia: W. B. Saunders Company, 2001; 764-90.
3. Sadler JE. Biochemistry and genetics of von Willebrand factor. Anna Rev Biochem 1998; 67: 395-424.
4. Ruggeri ZM. von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1: 1335-42.
5. Sadler JE. A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci USA 2002; 99: 11552-4.
6. Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Raemost 2001; 86: 178-88.
7. Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001; 86: 189-97.
8. Woodside DG, Liu S, Ginsberg MH. Integrin activation. Thromb Haemost 2001; 86: 316-23.
9. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
10. Mann KG, Lorand L. Introduction: blood coagulation. Methods Enzymol 1993; 222: 1-10.
11. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-6.
12. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
13. Dahlback B. Blood coagulation. Lancet 2000; 355: 1627-32.
14. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1: 1504-14.
15. Schenone M, Furie BC, Furie B. The blood coagulation cascade. Curr Opin Hematol 2004; 11: 272-7.
16. Di Cera E. Thrombin interactions. Chest 2003; 124(Suppl. 3): 11S-7.
17. Mann KG, van't Veer C, Cawthern K, Butenas S. The role of the tissue factor pathway in initiation of coagulation. Blood Coagul Fibrinolysis 1998; 9: S3-7.
18. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66-74.
19. Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 2000; 10: 139-43.
20. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17-20.
21. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17(Suppl. 1): S1-5.
22. Kalafatis M, Swords NA, Rand MD, Mann KG. Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1994; 1227: 113-29.
23. Zwaal RF, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta 1998; 10: 433-53.
24. Stenflo J, Dahlback B. Vitamin K-dependent proteins in blood coagulation. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, eds. The Molecular Basis of Blood Disease. 3rd edn. Philadelphia; W. B. Saunders Company, 2001; 579-613.
25. Krishnaswamy S, Nesheim ME, Pryzdial EL, Mann KG. Assembly of prothrombinase complex. Methods Enzymol 1993; 222: 260-80.
26. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
27. Federici AB. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 2003; 88: EREP02.
28. Huang M, Furie BC, Furie B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 2004; 279: 14338-46.
29. Zhang B, Ginsburg D. Familial multiple coagulation factor deficiencies: new biologic insight from rare genetic bleeding disorders. J Thromb Haemost 2004; 2: 1564-72.
30. Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004; 11: 170-5.
31. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001; 86: 57-65.
32. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1: 1566-74.
33. Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001; 86: 75-82.
34. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-52.
35. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res 1998; 39: 8-33.
36. Carmeliet P, Mackman N, Moons L et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-5.
37. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996; 88: 1583-7.
38. Bugge TH, Xiao Q, Kombrinck KW et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996; 93: 6258-63.
39. Rosen ED, Chan JC, Idusogie E et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390: 290-4.
40. Sun WY, Witte DP, Degen JL et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci USA 1998; 95: 7597-602.
41. Xue J, Wu Q, Westfield LA et al. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci USA 1998; 95: 7603-7.
42. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996; 384: 66-8.
43. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A[letter]. Nat Genet 1995; 10: 119-21.
44. Kundu RK, Sangiorgi F, Wu LY et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998; 92: 168-74.
45. Suh TT, Holmback K, Jensen NJ et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-33.
46. Nagashima M, Yin ZF, Zhao L et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
47. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-3.
48. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002; 22: 539-48.
49. Huang ZF, Higuchi D, Lasky N, Broze GJ Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 944-51.
50. van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol 1997; 34: 188-204.
51. Weitz JI. Heparan sulfate: antithrombotic or not? J Clin Invest 2003; 111: 952-4.
52. Ishiguro K, Kojima T, Kadomatsu K et al. Complete anti-thrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873-8.
53. Dahlbäck B, Stenflo J. The protein C anticoagulant system. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, eds. The Molecular Basis of Blood Disease. 3rd edn. Philadelphia: W. B. Saunders Company, 2001; 614-56.
54. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79: 109-16.
55. Esmon CT. The protein C pathway. Chest 2003; 124(Suppl. 3): 26S-32.
56. VandeWouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24: 1374-83.
57. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101: 20-30.
58. Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103: 1192-201.
59. Blom AM, Villoutreix BO, Dahlback B. Complement inhibitor C4b-binding protein - friend or foe in the innate immune system? Mol Immunol 2004; 40: 1333-46.
60. Webb JH, Blom AM, Dahlback B. Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol 2002; 169: 2580-6.
61. Webb JH, Blom AM, Dahlback B. The binding of protein S and the protein S-C4BP complex to neutrophils is apoptosis dependent. Blood Coagul Fibrinolysis 2003; 14: 355-9.
62. Bhopale GM, Nanda RK. Blood coagulation factor VIII: an overview. J Biosci 2003; 28: 783-9.
63. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
64. Dahlback B. Procoagulant and anticoagulant properties of coagulation factor V. Factor V Leiden (APC resistance) causes hypercoagulability by dual mechanisms. J Lab Clin Med 1999; 133: 415-22.
65. Nicolaes GA, Dahlback B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22: 530-8.
66. Jalbert LR, Rosen ED, Moons L et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998; 102: 1481-8.
67. Rosenberg RD. Thrombomodulin gene disruption and mutation in mice. Thromb Haemost 1997; 78: 705-9.
68. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost 2003; 1: 1515-24.
69. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol 2004; 25: 536-42.
70. Griffin JH, Zlokovic B, Fernandez JA. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol 2002; 39: 197-205.
71. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2.
72. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
73. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-94.
74. Sadler JE. von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-93.
75. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med 2005; 56: 173-91.
76. Lammle B, George JN. Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and treatment - introduction. Semin Hematol 2004; 41: 1-3.
77. Furlan M. Proteolytic cleavage of von Willebrand factor by ADAMTS-13 prevents uninvited clumping of blood platelets. J Thromb Haemost 2004; 2: 1505-9.
78. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003; 1: 625-31.
79. Tsai HM. Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. J Thromb Haemost 2003; 1: 2038-40; discussion 2040-5.
80. Collins PW. Management of acquired haemophilia A - more questions than answers. Blood Coagul Fibrinolysis 2003; 14 (Suppl. 1): S23-7.
81. Kraemer DM, Kraus MR. Acquired factor VIII haemophilia in a patient with acute necrotic pancreatitis. J Intern Med 2003; 254: 301-3.
82. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
83. Hay CR. Acquired haemophilia. Baillieres Clin Haematol 1998; 11: 287-303.
84. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004; 124: 567-76.
85. Dempfle CE. Coagulopathy of sepsis. Thromb Haemost 2004; 91: 213-24.
86. Lind SB. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-52.
87. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004; 30: 1032-40.
88. Berntorp E, Bjorkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9: 353-9.
89. Berntorp E. Prophylactic therapy for haemophilia: early experience. Haemophilia 2003; 9 (Suppl. 1): 5-9; discussion 9
90. Berntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 2001; 7: 109-13.
91. Kulkarni R, Aledort LM, Berntorp E et al. Therapeutic choices for patients with hemophilia and high-liter inhibitors. Am J Hematol 2001; 67: 240-6.
92. Di Michele DM. Immune tolerance: a synopsis of the international experience. Haemophilia 1998; 4: 568-73.
93. Brackmann HH, Effenberger W, Hess L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII. Eur J Haematol Suppl 1998; 63: 18-23.
94. Miller DG, Stamatoyannopoulos G. Gene therapy for hemophilia. N Engl J Med 2001; 344: 1782-4.
95. Berntorp E. Progress in haemophilic care: ethical issues. Haemophilia 2002; 8: 435-8.
96. Walsh CE. Gene therapy for the hemophilias. Curr Opin Pediatr 2002; 14: 12-6.
97. Monahan PE, White GC 2nd. Hemophilia gene therapy: update. Curr Opin Hematol 2002; 9: 430-6.
98. Lethagen S. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety. Semin Thromb Hemost 2003; 29: 101-6.
99. Lethagen S. Desmopressin - a haemostatic drug: state-of-the-art review. Eur J Anaesthesiol Suppl 1997; 14: 1-9.
100. Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 2004; 36: 41-9.
101. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001; 184: 258-74.
102. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004; 351: 268-77.
103. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
104. Nicolaes GA, Dahlback B. Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 2003; 17: 37-61.
105. Bertina RM. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. Clin Chem 1997; 43: 1678-83.
106. Lindqvist PG, Svensson PJ, Dahlbäck B, Marsal K. Factor V R506Q mutation (activated protein C resistance) associated with reduced intrapartum blood loss - a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
107. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76: 651-62.
108. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: part 2 [published erratum appears in Thromb Haemost 1997; 77: 1047]. Thromb Haemost 1996; 76: 824-34.
109. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: part 2 [published erratum appears in Thromb Haemost 1997; 77: 1047]. Thromb Haemost 1996; 76: 824-34.
110. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
111. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86: 83-91.
112. Triplett DA. Antiphospholipid-protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment). Haemostasis 1996; 4: 358-67.
113. Nicolaes GA, Dahlback B. Congenital and acquired activated protein C resistance. Semin Vasc Med 2003; 3: 33-46.
114. Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002; 126: 1349-66.
115. Persson KE, Dahlback B, Hillarp A. Diagnosing protein S deficiency: analytical considerations. Clin Lab 2003; 49: 103-10.
116. Bauer KA. Management of thrombophilia. J Thromb Haemost 2003; 1: 1429-34.
117. Schulman S. Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings. J Intern Med 1999; 245: 399-403.
118. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med 2003; 254: 322-34.
119. Koopman MM, Buller HR. Short- and long-acting synthetic pentasaccharides. J Intern Med 2003; 254: 335-42.
120. Lee AY, Vlasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med 2003; 254: 313-21.
121. Linkins LA, Weitz JI. New anticoagulants. Semin Thromb Hemost 2003; 29: 619-31.
122. Schulman S. Novel anticoagulant agents: introduction. J Intern Med 2003; 254: 308-12.